Last updated on April 20, 2014 at 14:04 EDT

Oramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial

July 8, 2013

Marks initiation of Oramed’s first FDA trial for its flagship ORMD-0801 oral insulin product

JERUSALEM, July 8, 2013 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer
of oral drug delivery systems, announced today that the first patient has been enrolled in
a Phase 2a trial of ORMD-0801, an orally ingestible insulin capsule, on patients with type
2 diabetes. The current trial is to be a randomized, double-blind study designed to assess
the safety of ORMD-0801.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 30 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801
[http://oramed.com/index.php?page=14 ]) currently initiating Phase 2 clinical trials on
patients with type 2 diabetes (T2DM) under an Investigational New Drug application with
the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a
GLP-1 analog [http://oramed.com/index.php?page=14 ]), with trials on healthy volunteers
(Phase 1b) and T2DM patients (Phase 2a) underway. The company’s corporate and R&D
headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements.
For example, we are using forward-looking statements when we discuss revolutionizing the
treatment of diabetes with our products, or when we discuss our clinical trials. These
forward-looking statements and their implications are based on the current expectations of
the management of Oramed only, and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection for our
product candidates; competition from other pharmaceutical or biotechnology companies; and
our ability to obtain additional funding required to conduct our research, development and
commercialization activities. In addition, the following factors, among others, could
cause actual results to differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is essential to
the development of our products; unforeseen scientific difficulties that may develop with
our process; greater cost of final product than anticipated; loss of market share and
pressure on pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient; and final
that products may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Oramed, reference
is made to Oramed’s reports filed from time to time with the Securities and Exchange

        Company Contact:
        Oramed Pharmaceuticals
        Aviva Sherman
        Office: +972-2-566-0001
        Mobile: +972-54-792-4438
        Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: PR Newswire